| 11.14 0.76 (7.32%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.92 |
1-year : | 16.26 |
| Resists | First : | 11.92 |
Second : | 13.92 |
| Pivot price | 10.65 |
|||
| Supports | First : | 10.07 |
Second : | 8.93 |
| MAs | MA(5) : | 10.39 |
MA(20) : | 10.54 |
| MA(100) : | 10.61  |
MA(250) : | 12.55 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 52.3 |
D(3) : | 41.2 |
| RSI | RSI(14): 54.2 |
|||
| 52-week | High : | 20.7 | Low : | 8.93 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ URGN ] has closed below upper band by 30.2%. Bollinger Bands are 19.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.42 - 11.47 | 11.47 - 11.52 |
| Low: | 9.59 - 9.64 | 9.64 - 9.69 |
| Close: | 11.04 - 11.14 | 11.14 - 11.23 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Mon, 12 May 2025
UroGen Pharma (URGN) Awaits FDA Decision on UGN-102 - GuruFocus
Mon, 12 May 2025
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update - ADVFN
Mon, 12 May 2025
Analyst Maintains Buy Rating for UroGen Pharma (URGN) | URGN Sto - GuruFocus
Mon, 12 May 2025
Urogen Pharma Ltd reports results for the quarter ended March 31 - Earnings Summary - TradingView
Mon, 12 May 2025
UroGen (URGN) Awaits FDA Decision on Promising Bladder Cancer Tr - GuruFocus
Mon, 12 May 2025
UroGen Pharma Reports First Quarter 2025 Financial Results and P - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 46 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 8.3 (%) |
| Held by Institutions | 86.7 (%) |
| Shares Short | 5,020 (K) |
| Shares Short P.Month | 5,650 (K) |
| EPS | -2.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.21 |
| Profit Margin | -140.4 % |
| Operating Margin | -108.2 % |
| Return on Assets (ttm) | -25.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 4.4 % |
| Gross Profit (p.s.) | 1.76 |
| Sales Per Share | 1.96 |
| EBITDA (p.s.) | -2.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -97 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -3.77 |
| PEG Ratio | 0 |
| Price to Book value | -53.05 |
| Price to Sales | 5.68 |
| Price to Cash Flow | -5.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|